Skip to main content
ASCPT 2023 Annual Meeting Main banner
Back

Mark J. Dresser, PhD (he/him/his)

Senior Vice President
Gilead Sciences

Dr. Dresser currently serves as Senior Vice President, Biomarker Sciences and Clinical Pharmacology at Gilead Sciences, where he oversees R&D efforts spanning biomarkers, diagnostics, clinical translational science, clinical pharmacology, pharmacometrics, and clinical bioanalysis. Dr. Dresser was previously Senior Vice President, Development Sciences, and a founding member of the executive team at Denali Therapeutics, where he built numerous technical departments, including DMPK, Toxicology, and CMC. Under his leadership, Denali advanced five compounds into clinical development, and he also played a key role in the company’s successful IPO in 2017.
Prior to joining Denali, Dr. Dresser was the Head of the Oncology Clinical Pharmacology Department and the Atezolizumab (anti-PD-L1) Project Team Leader at Genentech. He started his career at Johnson & Johnson, where he contributed to early- and late-stage clinical development programs. Dr. Dresser received his PhD from UCSF and his BS and MS degrees in chemistry from Rensselaer Polytechnic Institute and the Swiss Federal Institute of Technology. In 2019, Mark received the UCSF Graduate Division Alumnus of the Year Award for his contributions to science and medicine, and in 2022 he was named one of 15 leaders giving voice and visibility to the LGBTQIA+ community in biopharma by Endpoints News.

Presentation(s):